WSE:IGN

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Inno-Gene S.A. provides genetic diagnostic solutions in Poland. More Details


Snowflake Analysis

Adequate balance sheet with poor track record.

Share Price & News

How has Inno-Gene's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: IGN's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

5.3%

IGN

0.5%

PL Life Sciences

-0.6%

PL Market


1 Year Return

3,698.1%

IGN

81.1%

PL Life Sciences

-17.5%

PL Market

Return vs Industry: IGN exceeded the Polish Life Sciences industry which returned 82.3% over the past year.

Return vs Market: IGN exceeded the Polish Market which returned -16.6% over the past year.


Shareholder returns

IGNIndustryMarket
7 Day5.3%0.5%-0.6%
30 Day367.5%4.0%-1.8%
90 Day310.4%9.4%-10.2%
1 Year3,698.1%3,698.1%82.0%81.1%-16.8%-17.5%
3 Year2,731.5%2,731.5%131.2%126.2%-26.0%-30.4%
5 Year912.8%912.8%282.0%257.7%-16.0%-25.1%

Price Volatility Vs. Market

How volatile is Inno-Gene's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Inno-Gene undervalued compared to its fair value and its price relative to the market?

1260.03x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate IGN's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate IGN's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: IGN is poor value based on its PE Ratio (1260x) compared to the XE Life Sciences industry average (62.8x).

PE vs Market: IGN is poor value based on its PE Ratio (1260x) compared to the Polish market (12.6x).


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate IGN's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: IGN is overvalued based on its PB Ratio (154.5x) compared to the XE Life Sciences industry average (5.5x).


Next Steps

Future Growth

How is Inno-Gene forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

18.3%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Inno-Gene has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Inno-Gene performed over the past 5 years?

19.6%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: IGN has a large one-off gain of PLN56.5K impacting its June 30 2020 financial results.

Growing Profit Margin: IGN's current net profit margins (20.8%) are lower than last year (27.1%).


Past Earnings Growth Analysis

Earnings Trend: IGN has become profitable over the past 5 years, growing earnings by 19.6% per year.

Accelerating Growth: IGN's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: IGN had negative earnings growth (-44.4%) over the past year, making it difficult to compare to the Life Sciences industry average (28.5%).


Return on Equity

High ROE: IGN's Return on Equity (7.8%) is considered low.


Next Steps

Financial Health

How is Inno-Gene's financial position?


Financial Position Analysis

Short Term Liabilities: IGN's short term assets (PLN3.3M) do not cover its short term liabilities (PLN13.8M).

Long Term Liabilities: IGN's short term assets (PLN3.3M) exceed its long term liabilities (PLN285.4K).


Debt to Equity History and Analysis

Debt Level: IGN's debt to equity ratio (27.1%) is considered satisfactory.

Reducing Debt: Insufficient data to determine if IGN's debt to equity ratio has reduced over the past 5 years.

Debt Coverage: IGN's debt is well covered by operating cash flow (178.9%).

Interest Coverage: IGN earns more interest than it pays, so coverage of interest payments is not a concern.


Balance Sheet


Next Steps

Dividend

What is Inno-Gene current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate IGN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate IGN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if IGN's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if IGN's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of IGN's dividend in 3 years as they are not forecast to pay a notable one for the Polish market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?


CEO

Jacek Wojciechowicz

no data

Tenure

Mr. Jacek Wojciechowicz serves as President and R&D Director at Centrum Badan DNA Sp. z o.o. Mr. Wojciechowicz serves as the President of the Management Board at Inno-Gene S.A.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: IGN insiders have only sold shares in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Inno-Gene S.A.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Inno-Gene S.A.
  • Ticker: IGN
  • Exchange: WSE
  • Founded: 2006
  • Industry: Life Sciences Tools and Services
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: zł450.385m
  • Shares outstanding: 5.70m
  • Website: https://www.inno-gene.pl

Number of Employees


Location

  • Inno-Gene S.A.
  • Poznan Science and Technology Park
  • 46 Rubiez str.
  • Poznan
  • 61-612
  • Poland

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
IGNWSE (Warsaw Stock Exchange)YesCommon Bearer SharesPLPLNFeb 2011

Biography

Inno-Gene S.A. provides genetic diagnostic solutions in Poland. It engages in the research and diagnostic center implementation; and the provision of technologies in the field of DNA analysis. The company ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/10/21 20:44
End of Day Share Price2020/10/21 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.